

Good Morning,

Thank you for the opportunity to provide comment on the draft Review Terms of Reference for the post-market review of ezetimibe.

As the national peak body representing the needs of Australians affected by all forms of kidney disease, Kidney Health Australia would like the Terms of Reference to explicitly consider improved patient outcomes for people with cardiovascular disease and/or at risk of stroke as a core focus of the Review.

Kidney Health Australia is keen to remain involved in this Review, and I would appreciate being added to your mailing list for updates, particularly with regards to any opportunities to provide submissions to the Review.

Kind regards,  
Marie Ludlow

**Dr Marie Ludlow (PhD) | National Medical Manager | [Kidney Health Australia](#)**

[Redacted contact information]